Congress caps insulin copays at $35, funds uninsured access pilot.
S. 4189 — INSULIN Act of 2026 · Filed by Jeanne Shaheen (D-NH) · 28 cosponsors · Introduced Mar 25, 2026 · Reported out
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill caps insulin cost-sharing at $35 per 30-day supply for insured patients starting in 2028, eliminates deductibles for selected insulin products, and prevents insurers from imposing prior authorization on insulin without clinical justification. It also funds a pilot program to help uninsured individuals access affordable insulin, establishes a resource center and hotline for uninsured patients, accelerates generic and biosimilar insulin approvals by tightening rules on delay-tactic citizen petitions, and directs a study on uninsured insulin users.
Why we flagged it
The bill's core mechanism is a direct price cap on insulin copays for insured patients, combined with new access programs for the uninsured and regulatory streamlining to accelerate generic/biosimilar competition. This is consumer-protection legislation, not a tax or subsidy carve-out.
What the text implies
- The $35 copay cap applies only to 'selected insulin products' chosen by insurers, not all insulins—insurers retain discretion over which products qualify, potentially steering patients toward preferred formulations and limiting choice.
- The bill exempts insulin copay relief from actuarial value calculations under the ACA, preventing it from triggering higher premiums for other benefits; this is a technical fix but may obscure the true cost-shifting to insurers and employers.
The full analysis lists 5 implications of this text.
Who stands to gain
Insured patients (direct copay relief); Uninsured individuals in pilot states (grant-funded access); Generic and biosimilar insulin manufacturers (accelerated approval pathway)